{"id":"W2113950318","doi":"10.1111/bjh.13493","title":"A phase <scp>II</scp> trial of <scp>RCHOP</scp> followed by radioimmunotherapy for early stage (stages I/<scp>II</scp>) diffuse large B‐cell non‐Hodgkin lymphoma: <scp>ECOG</scp>3402","year":2015,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Pharmacyclics; Genentech; ECOG-ACRIN Cancer Research Group; Roche; American College of Radiology Imaging Network; Spectrum Pharmaceuticals; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Radioimmunotherapy; Medicine; Diffuse large B-cell lymphoma; Rituximab; Chemoimmunotherapy; Internal medicine; Phases of clinical research; Lymphoma; Nuclear medicine; Clinical trial; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001100293,0.001077959,0.0009768174,0.0003665294,0.000346084,0.0005498449,0.000422549,0.0007433667,0.003412557],"category_scores_gemma":[0.0003205579,0.0002889908,0.001036017,0.0002964496,0.0004453542,0.0002873747,0.0002579688,0.001934169,0.0006684803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005395771,"about_ca_system_score_gemma":0.001074377,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001134514,"about_ca_topic_score_gemma":0.003433042,"domain_scores_codex":[0.9997634,0.0001252528,0.00001064214,0.00002868446,0.00002350403,0.00004853734],"domain_scores_gemma":[0.9997085,0.00003689771,0.00004763525,0.00002542241,0.00002544064,0.000156093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6028094,0.05462248,0.008153491,0.001785196,0.001924091,0.0004302818,0.0002708236,0.00330974,0.07144839,0.0008952662,0.01351959,0.2408313],"study_design_scores_gemma":[0.6249092,0.3443831,0.01421705,0.0001124297,0.0004441048,0.0004187979,0.00004738541,0.001502182,0.005292436,0.0002815479,0.008368159,0.00002359463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842585,0.002676973,0.0007433055,0.0005716273,0.0001925758,0.005354661,0.001033153,0.0001515767,0.005017681],"genre_scores_gemma":[0.9770946,0.002680389,0.002848778,0.002047017,0.0002323184,0.004453437,0.00412983,0.00004281133,0.006470903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003412557,"threshold_uncertainty_score":0.01141608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01910968422061875,"score_gpt":0.2890661712795868,"score_spread":0.269956487058968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}